CRISPR Archives

News and Trends 10 May 2023

Scientists create first CRISPR-based drug candidate targeting the microbiome

A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections. Many people have experienced infections from E. coli, which are […]

May 10, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

New discovery “an area of cancer research with tremendous promise for breakthroughs”

A research team led by Gary Ying Wai Chan from the School of Biological Sciences at The University of Hong Kong (HKU), has revealed the function of a unique enzyme, ANKLE1. ANKLE1 acts on chromatin bridges trapped in the midzone of dividing cells. By cutting these bridges, ANKLE1 prevents damage to the genetic material and […]

April 21, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 12 Apr 2023

New technique developed for safer gene editing

CRISPR-Cas9 is widely used to edit the genome by studying genes of interest and modifying disease-associated genes. However, this process can be associated with potential side effects, including unwanted mutations and toxicity. Researchers at Kyushu University and Nagoya University School of Medicine in Japan have developed an optimized genome-editing method that vastly reduces mutations, opening […]

April 12, 2023 - 4 minutesmins - By Jim Cornall

In Depth 10 Mar 2023

Can CRISPR bring back extinct animals?

The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as mammoths an extremely feasible proposition that investors are willing to put their money into, with an aim of reversing and preventing biodiversity loss. The […]

March 10, 2023 - 10 minutesmins - By Willow Shah-Neville

News and Trends 23 Feb 2023

Sherlock obtains Cas12 CRISPR patent

Sherlock Biosciences, a company engineering biology to bring next-generation lab-quality diagnostic testing to the point of need, has announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme. Sherlock Biosciences has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Can CRISPR correct type 2 diabetes gene?

Swedish researchers have identified 395 genes that are differently expressed in people with type 2 diabetes. One of these (PAX5) has proven to be very strongly associated with impaired insulin secretion. Now, researchers want to investigate if it is possible to use the genetic CRISPR/Cas9 scissors to correct the gene’s activity. The research team’s scientific […]

February 21, 2023 - 3 minutesmins - By Jim Cornall

Expert Advice 16 Feb 2023

Five things you need to know about using CRISPR/Cas9 commercially

By Michael Arciero, vice president of intellectual property and corporate development, ERS Genomics CRISPR/Cas9 gene editing technology is a patented invention, so any commercial use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape for CRISPR/Cas9 is clearer than you may think. Here are the 5 key facts […]

February 16, 2023 - 6 minutesmins - By External Contributor

News and Trends 3 Feb 2023

AI boosts genome editing

Researchers at the University of Zurich have developed a new tool that uses artificial intelligence to predict the efficacy of various genome-editing repair options. Unintentional errors in the correction of DNA mutations of genetic diseases can thus be reduced. Genome editing technologies offer great opportunities for treating genetic diseases. Methods such as the widely used […]

February 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Milestone for gene-edited therapy for sickle cell disease

Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of exa-cel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The submission is supported by two global phase 3 studies investigating exa-cel as a potential one-time therapy for people with […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 20 Jan 2023

Aldevron launches type-V CRISPR Nuclease

Aldevron, which develops and manufactures plasmid DNA, RNA and proteins for the biotech industry, has launched Eureca-V Nuclease, the wild-type MAD7 CRISPR Type-V nuclease, licensed from Inscripta, at Research Grade, with GMP to follow.   Aldevron’s launch at Advanced Therapies Week of Eureca-V Nuclease expands the toolkit of available CRISPR nucleases for therapeutic, diagnostic, and agricultural […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

Ensoma acquiring Twelve Bio

Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced that portfolio company Twelve Bio will be acquired by Ensoma in connection with an $85 million financing of Ensoma which Arix co-led, investing $9 million. Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

Researchers discover new type of CRISPR gene scissors

Scientists at the Helmholtz Institute Würzburg in Germany, and Benson Hill, Inc. (Missouri) and Utah State University in the U.S., have found a nuclease, which they dubbed Cas12a2, that represents an entirely new type of CRISPR immune defense. Unlike any other previously known nuclease of the CRISPR-Cas immune system, the source of ‘gene scissors,’ Cas12a2 […]

January 5, 2023 - 4 minutesmins - By Jim Cornall

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CRISPR

Scientists create first CRISPR-based drug candidate targeting the microbiome

New discovery “an area of cancer research with tremendous promise for breakthroughs”

New technique developed for safer gene editing

Can CRISPR bring back extinct animals?

Sherlock obtains Cas12 CRISPR patent

Can CRISPR correct type 2 diabetes gene?

Five things you need to know about using CRISPR/Cas9 commercially

AI boosts genome editing

Milestone for gene-edited therapy for sickle cell disease

Aldevron launches type-V CRISPR Nuclease

Ensoma acquiring Twelve Bio

Researchers discover new type of CRISPR gene scissors

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!